

Carbohydrate-binding modules such as CBM41d aid in the capture of starch by Eubacterium rectale in the human intestine.



82x80mm (300 x 300 DPI)

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version record. Please cite this article as doi:10.1111/mmi.13881.

Gut bacteria attach to dietary fiber such as starch via carbohydrate binding modules (CBMs). Here we demonstrate that a cell surface starch-degrading enzyme Amy13K from the prominent gut bacterium *Eurbacterium rectale* harbors five CBMs that have different specificities and affinity for starch. The specificity of the Amy13K CBMs provides a molecular rationale for why *E. rectale* is only able to process certain types of dietary starch in the human large intestine.

epten Acce

Novel carbohydrate binding modules in the surface anchored  $\alpha$ -amylase of *Eubacterium rectale* provide a molecular rationale for the range of starches used by this organism in the human gut.

Darrell W. Cockburn<sup>1,2</sup>, Carolyn Suh<sup>1</sup>, Krizia Perez Medina<sup>1</sup>, Rebecca M. Duvall<sup>1</sup> Zdzislaw Wawrzak<sup>3</sup> Bernard Henrissat<sup>4,5,6</sup> and Nicole M. Koropatkin<sup>1\*</sup>

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

<sup>2</sup> Department of Food Science, Pennsylvania State University, University Park, PA 16802, USA

<sup>3</sup> Argonne National Laboratory, 9700 S. Cass Avenue, Argonne, IL 60439, USA

<sup>4</sup> Architecture et Fonction des Macromolécules Biologiques, CNRS, Aix-Marseille University, F-13288

Marseille, France

<sup>5</sup> Institut National de la Recherche Agronomique, USC1408 Architecture et Fonction des

Macromolécules Biologiques, F-13288 Marseille, France

<sup>6</sup> Department of Biological Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia

<sup>\*</sup> For correspondence. E-mail nkoropat@umich.edu; Tel. (+1) 734 647 5718; Fax (+1) 734 764 3562

Keywords: carbohydrate binding module; α-amylase; resistant starch; gut microbiome

Running Title: Novel CBMs dictate E. rectale starch utilization

### Summary

Gut bacteria recognize accessible glycan substrates within a complex environment. Carbohydrate binding modules (CBMs) of cell-surface glycoside hydrolases often drive binding to the target substrate. *Eubacterium rectale*, an important butyrate-producing organism in the gut, consumes a limited range of substrates, including starch. Host consumption of resistant starch increases the abundance of *E*. *rectale* in the intestine, likely because it successfully captures the products of resistant starch degradation by other bacteria. Here we demonstrate that the cell wall anchored starch-degrading α-amylase, Amy13K of *E. rectale* harbors five CBMs that all target starch with differing specificities. Intriguingly these CBMs efficiently bind to both regular and high amylose corn starch (a type of resistant starch), but have almost no affinity for potato starch (another type of resistant starch). Removal of these CBMs from Amy13K reduces the activity level of the enzyme towards corn starches by ~40-fold, down to the level of activity towards potato starch, suggesting that the CBMs facilitate activity on corn starch and allowing its utilization *in vivo*. The specificity of the Amy13K CBMs provides a molecular rationale for why *E. rectale* is able to only use certain starch types without the aid of other

organisms.

Acce

### Introduction

The human gut microbiota consists of trillions of individual bacteria and the interaction of this dense microbial population with our diet and other environmental factors is an important determinant of our health. A healthy microbiome is protective against a number of conditions including colon cancer (Zackular *et al.*, 2013), inflammatory bowel disease (De Cruz *et al.*, 2015, Rajilic-Stojanovic *et al.*, 2013), diabetes (Forslund *et al.*, 2015) and obesity (Ridaura *et al.*, 2013). Saccharolytic gut bacteria offer particular benefits, persisting in the host through the fermentation of fiber, carbohydrates that human enzymes are unable to process (Shanahan *et al.*, 2017). One prominent fiber in the human diet is resistant starch, starches that for a variety of reasons are indigestible by human enzymes, but are susceptible to attack by certain microorganisms (Birt *et al.*, 2013). Uncooked potato starch is one such resistant starch as it adopts an alternative crystal structure, known as the B-type structure, compared to the more easily digestible wheat and corn starches (Imberty *et al.*, 1991). In corn, certain mutations result in a higher relative abundance of amylose in the starch granules. This high amylose corn starch also adopts the B-type crystalline structure and is a resistant starch (Gallant *et al.*, 1992). The end result of resistant starch and other carbohydrate fermentation in the gut is often organic acids, particularly the short chain fatty acids (SCFA) acetate, propionate, and butyrate (Rios-Covian *et al.*, 2016).

While SCFAs have been shown to influence our physiology (Berggren *et al.*, 1996, Wong *et al.*, 2006, Boets *et al.*, 2016), butyrate has been particularly noted for its health promoting effects (Guilloteau *et al.*, 2010). This SCFA can provide as much as 10% of our daily caloric intake (McNeil, 1984) and it is the preferred energy source of colonocytes (Roediger, 1980). Butyrate increases the rate of proliferation of colonocytes and strengthens tight junctions (Wang *et al.*, 2012), improving gut barrier function. It increases the rate of apoptosis for malignant cells, protecting against colon cancer (Fung *et al.*, 2012). Butyrate also downregulates the expression of pro-inflammatory cytokines, leading to lower levels of inflammation in the gut (Nastasi *et al.*, 2015). When processed in the liver, butyrate shifts glucose metabolism towards storage as glycogen (Beauvieux *et al.*, 2008), thereby protecting against the development of diabetes. Thus, butyrate is clearly a critical regulator of health making it important to understand the unique physiology of the bacteria responsible for its production.

One of the most prominent groups of butyrate-producing organisms in the gut is the cluster XIVa clostridia, exemplified by one of their most abundant members, Eubacterium rectale. This Gram positive organism has long been recognized as a dominant species in the human gut (Gossling & Slack, 1974) and a core member of the healthy microbiome (Tap et al., 2009). E. rectale decreases in abundance in a number of disease states, including obesity (Haro et al., 2016), inflammatory bowel disease (Kang et al., 2010, Rajilic-Stojanovic et al., 2013), diabetes (Qin et al., 2012) and cystic fibrosis (Bruzzese et al., 2014). Intriguingly, E. rectale levels are found to increase, along with butyrate levels, in diets rich in resistant starch (Martínez et al., 2010, Martínez et al., 2013). However, in vitro studies indicate that it is unable to directly use resistant starch, though it grows robustly in the presence of a primary resistant starch degrader such as Ruminococcus bromii (Ze et al., 2012). Our recent study of the cell wall and membrane proteome of E. rectale when grown on starch as compared to glucose, revealed that two ABC transporters that target different maltooligosaccharides, along with two amylases were strongly upregulated in the presence of starch. Thus we proposed a model by which the larger cell surface amylase EUR 21100 plays a crucial role in the organism's growth on starch, cleaving starch molecules into maltotetraose and larger oligosaccharides, which is directly bound by the ABC transporter solute-binding protein EUR\_01830 (Cockburn et al., 2015b). Here we present a structural and functional characterization of the cell surface amylase EUR\_21100, which we have renamed Amy13K, and demonstrate empirically that Amy13K contains five discrete starch-binding CBMs that establish two new CBM families and are critical for starch processing. These new CBM families exhibit an extremely narrow taxonomic distribution, suggesting that they are highly adapted to the niche of E.

### This article is protected by copyright. All rights reserved.

*rectale* in the human gut. These CBMs effectively target corn starch, including high amylose corn starch, but bind poorly to potato starch, explaining the weak activity of the enzyme against this substrate and why the organism cannot grow on resistant potato starch.

Results

### Amy13K harbors CBMs that define novel families

We previously reported that *E. rectale* Amy13K (EUR\_21100) was likely comprised of five CBMs at its Nterminus based upon weak sequence homology to the starch-binding families CBM26 (BLAST E-value 2e<sup>-5</sup>) and CBM41 (BLAST E-value 1e<sup>-5</sup> – 5e<sup>-7</sup>) (Cockburn *et al.*, 2015b). The biochemical and structural data presented here supports that there are five CBMs, labeled as CBMa-e, and two warrant classification into new CBM families (Fig 1) within the Carbohydrate Active enZymes database: www.cazy.org (Lombard *et al.*, 2014). CBMb and CBMc showed similarity to several CBM26 modules (Fig 51) allowing them to be placed in this family. Similarly CBMd showed relatedness to several CBMs classified as CBM41 and thus was assigned to that family (Fig 52). CBMa and CBMe did not show similarity to known CBM families or to each other. A BLAST search was then conducted against full length proteins in CAZy to identify similar domains. CBMa and its homologs (Fig S3) were classified in a new CBM family called CBMxy (final numbering given at proof stage), while CBMe and its homologs define family CBMyz (Fig S4) (final numbering given at proof stage).

The sequences of CBMb and CBMc identify them as members of the CBM26 family and their structures presented here (later in Fig 3) point to their structural relationship to members of this family as well. The CBM26 domains are typically associated with  $\alpha$ -amylases, including enzymes from bacteria related to *E. rectale* (Ramsay *et al.*, 2006). According to Pfam (pfam.xfam.org) CBM26s occur in tandem repeats approximately one third of the time. Conversely, CBMd can be placed within the CBM41 family, though it is a somewhat distant relative, exhibiting only a 28% sequence identity with its closest relative within the family. Despite this, it can be placed within subfamily 5 of this group, which includes the T. maritima PulA CBM41, its closest structural homologue (Janecek et al., 2017). This group is characterized by the pattern of its aromatic residues with W-X-W-~30aa-W, with the first tryptophan acting as a hydrogen-bonding residue, while the second and third form the aromatic binding platform for starch recognition. These residues are W416, W418 and W469 in CBMd. While the 51 amino acid distance between the second and third tryptophan is larger than the typical distance seen in this subfamily, there is some variability in this distance (Janecek et al., 2017). This atypical distance and the overall low sequence identity with its fellow family members may be due to the fact that there are no prior examples of CBM41s from organisms closely related to *E. rectale*, as the CBMs in this family cluster along taxonomic lines (Janecek et al., 2017). Intriguingly Pfam indicates that CBM41s occur as tandem pairs a slight majority of the time. This suggests that the new CBMxy family may be evolutionarily related to CBM41 and has diverged over time. In general the CBM41 family of binding domains is typically associated with pullulanases, *i.e.*  $\alpha$ -1,6 specific enzymes. The catalytic domain of Amy13K is related to the pullulanase subfamilies (GH13\_12 and GH13\_14) (Cockburn et al., 2015b, Møller *et al.*, 2016), though the enzyme itself is an  $\alpha$ -amylase, *i.e.*  $\alpha$ -1,4 specific (Cockburn *et al.*, 2015b) and assigned to subfamily GH13 41. Interestingly the GH13 41 domains are typically found in multidomain proteins in conjunction with one of the pullulanase families mentioned above (Møller et al., 2016) suggesting GH13 41 may have arisen from duplication of the pullulanase domains followed by further evolution or vice versa.

Intriguingly CBMa and CBMe each represent novel, previously uncharacterized CBM families. Their narrow distribution among similar gut bacteria within the Lachnospiraceae points to the highly specialized nature of these binding modules. Having a single large enzyme with a variety of adapted starch specific CBMs seems to be employed by a number of members of the Lachnospiraceae. Both *Roseburia inulinovorans* and *Butyrivibrio fibrosolvens* possess a large cell-associated amylase (Ramsay

*et al.*, 2006). The catalytic domain of Amy13K and *R. inulinovorans* Amy13a both belong to the GH13\_41 subfamily and the Amy13K\_CBMa has a strong resemblance to the N-terminal R1 and R2 domain of Amy13a and together are part of the newly defined family CBMxy (Fig S3). Additionally, the previously described PUD domain (now CBM41) of Amy13a, is similar to Amy13K\_CBMd and both also have CBMs that are part of the new CBMyz family (Fig S4). While both enzymes have large N-terminal regions upstream of their catalytic domains, these regions have little sequence similarity other than the domains already mentioned. In contrast the *B. fibrosolvens* protein has an entirely different domain organization with the catalytic domain at the C-terminus, followed by a pair of CBM26 domains. Thus members of this family of bacteria seem to have diverged over time with regards to their machinery for starch digestion, perhaps as part of their segregation into subtly different niches within the gut.

# Crystal structures of Amy13K CBMd (CBM41) and CBMbc (CBM26)

We performed extensive crystallization trials on all CBM constructs, yet were only successful in obtaining crystals and structures of three domains: CBMd and CBMbc. Crystallization trials of CBMde yielded crystals of CBMd alone after several months, suggesting flexibility between the domains inhibited crystal formation until proteolysis occurred. Attempts to produce crystals of CBMe alone were unsuccessful. The structure of Amy13K\_CBMd was solved to a resolution of 2.20 Å ( $R_{work} = 23.4\%$ ,  $R_{free} = 25.7\%$ ) revealing a  $\beta$ -sandwich fold like other CBM41 structures (Fig 2A). A search of the DALI server suggests that the closest structural relatives of CBMd are the CBM41 domain of *Thermotoga maritima* pullulanase PulA (PDB 2J73, Z-score = 10.6) (Lammerts van Bueren & Boraston, 2007), which also shares 22% sequence identity, and the CBM41 domains of *Streptococcus pneumoniae* alkaline amylopullanase SpuA (PDB 2J44, Z-score = 9.3) (Lammerts Van Bueren *et al.*, 2004b). Overall the secondary structure elements of CBMd align well with those of the CBM41s from PulA and SpuA with the major differences confined to loop regions. An overlay of the structure of CBM41 with that of CBM41 in PulA with

bound maltotriose (PDB 2J73) identified the putative starch-binding site by conservation with similar starch-binding residues in PulA (Fig 2B). In PulA, the aromatic platform comprised of W29 and W73 overlays well with residues W418 and W469 of CBMd. Likewise in CBMd, additional hydrogen-bonding to the hydroxyl oxygens of adjacent glucose residues may be supported by W416, K460, and D477, which are present as W27, K76 and D81 in PulA. As seen in many starch-binding proteins, the aromatic binding platform forms the classic convex angle that matches the helical pitch of amylose and amylopectin chains (Imberty *et al.*, 1991). This orientation is seen in diverse starch-binding proteins ranging from dedicated starch-binding proteins like SusD (Koropatkin *et al.*, 2008), to CBMs (Boraston *et al.*, 2006) and surface binding sites on amylolytic enzymes (Cockburn & Svensson, 2016).

We determined the crystal structure of CBMbc with maltoheptaose (2.01 Å,  $R_{work} = 18.9\%$ ,  $R_{free} = 20.0\%$ ) and without (2.10 Å,  $R_{work} = 20.8\%$ ,  $R_{free} = 23.2\%$ )(Fig 3A). In the substrate bound structure, the maltoheptaose molecule bound to CBMb spans across adjacent asymmetric units and likely facilitated crystallization. The structures of the free and maltoheptaose bound proteins overlay well with an RMSD <0.4 Å for all C $\alpha$  atoms, and thus no structural change occurs upon ligand binding. Both CBMb and CBMc display bound maltoheptaose with some minor differences. Both CBMs possess a pair of aromatic residues at the center of the binding interface, however in CBMb these are a tyrosine (Y198) and a tryptophan (W208), while in CBMc they are a pair of tryptophans (W299, W314) (Fig 3B,C). Comparing the CBMs, the phenol ring of Y198 overlays with the indole ring of W299, while there is a 2.4 Å separation between the relative positions of W208 and W314. In addition to the aromatic binding platform there are several conserved hydrogen bonds between the two CBMs. The Y196 and Y297 hydroxyl groups form hydrogen bonds with the O6 of the glucose stacking on Y198 and W299, respectively, while Q247 and Q352, form hydrogen bonds with both the O2 and O3 of the glucose stacked on W208 and W314, respectively. In CBMc N355 forms a hydrogen bond with the O3 of the glucose stacked on W299, however, the equivalent residue in CBMb, D250, has a water-mediated

### This article is protected by copyright. All rights reserved.

contact with the O2 of the glucose stacked on Y198. A loop spanning from K199 to P204 in chain A of CBMb diverges in position from the equivalent loop in CBMc (A301-A308) and forms contacts with the glucose residues of the maltoheptaose molecule as it spans into the neighboring asymmetric unit into the binding site of CBMc. This places E200 and N202 of CBMb chain A in hydrogen bonding position with the maltoheptaose molecule as it extends out of the CBMb binding site, potentially expanding the CBMb binding site (Fig 3B, Fig S5). The equivalent loop in CBMc from A301-A308 is composed of smaller sidechains, packing into the body of the CBM and does not appear to be capable of making additional contacts to a longer sugar.

Like CBMd, both CBMb and CBMc exhibit the typical  $\beta$ -sandwich fold seen in many CBMs (Fig 3A). DALI searches reveal that the closest structural matches for CBMb/c are the CBM25 (2C3X, Z-score = 11.7/10.5) and CBM26 (2C3H, Z-score = 10.7/10.1) from *Bacillus halodurans*  $\alpha$ -amylase (Boraston *et al.*, 2006) along with the CBM25 from the *Paenibacillus polymyxa*  $\beta/\alpha$ -amylase (PDB 2LAA, Z-score = 10.7/10.1). Somewhat weaker matches are found to the CBM41 family of domains, despite our previous suggestion that CBMbc might be members of this family (Cockburn *et al.*, 2015b). An overlay with the CBM26 from *B. halodurans* (2C3H) shows a high degree of overlap between the aromatic platform residues from both CBMb and c, as well as some of the hydrogen bonding residues of these CBMs. Of note, Y196/Y297 from CBMb/c with Y23 from *B. halodurans* CBM26 as well as Q247/352 from CBMb/c with Q71 from *B. halodurans* CBM26 (Fig 3D,E) are superimposable. Thus it appears that CBMb and CBMc are most structurally homologous to CBM26, supporting their placement within this family.

Amy13K CBMs bind soluble starch and oligosaccharides

A total of six recombinant protein constructs were used in this study to test the ability of the Amy13K CBMs to bind to starch (Fig 1). The CBMs were expressed independently (*e.g.* CBMa) or in combination (*e.g.* CBMa-e) to examine how they might synergize to enhance starch-binding. Both affinity

electrophoresis and isothermal titration calorimetry (ITC) were used to determine the binding of the constructs to polymers and smaller maltooligosaccharides. In affinity electrophoresis binding is monitored via migration of the protein through an acrylamide gel in the presence or absence of ligand and slower migration occurs as the protein interacts with polysaccharide (Cockburn et al., 2017, Abbott & Boraston, 2012). By affinity electrophoresis, all of the CBM constructs except the CBMe construct displayed binding to both amylopectin and pullulan (Fig 4). While amylopectin is one of the two components of starch along with amylose, pullulan is a linear fungal cell wall polysaccharide composed of  $\alpha$ -1,6 linked maltotriose residues. Like amylopectin, pullulan contains both  $\alpha$ -1,4 and  $\alpha$ -1,6 linkages, however, it is linear rather than branched and has a much greater frequency of  $\alpha$ -1,6 bonds, occurring every three linkages (Prajapati et al., 2013). Thus it serves as a model substrate for de-branching enzymes and can be useful for determining the tolerance for and importance of  $\alpha$ -1,6 linkages for binding (Cockburn et al., 2015a). While CBMa and CBMbc display slower migration in the presence of amylopectin, which has longer regions of  $\alpha$ 1,4-linked glucan, the CBMde construct is slowed much more by the presence of pullulan. Enhanced binding to pullulan could be driven by specific interactions with CBMd or due to enhanced avidity from the tandem CBM construct. Indeed, longer constructs such as CBMb-e and CBMa-e also displayed some enhanced binding to pullulan over amylopectin, either due to the presence of CBMde or by avidity. From the crystal structure of CBMd without substrate, it is difficult to speculate how this CBM may specifically accommodate  $\alpha$ 1,6 linkages, however, it may be the influence of the  $\alpha$ 1,6 bond on the surrounding structure that is recognized. The  $\alpha$ 1,6 bond introduces considerable structural flexibility relative to  $\alpha 1,4$  bonds, resulting in pullulan behaving as a random coil in solution compared to the helices formed by amylose (Dais et al., 2001). In starch, the branch points cause the creation of amorphous layers that alternate with the longer linear regions that make up the crystalline layers (Damager *et al.*, 2010). Thus it takes 3-6 glucose residues after an  $\alpha$ 1,6 linkage before regular helices begin to form (Motawia et al., 2005) and it is possible that CBMd and or

### This article is protected by copyright. All rights reserved.

CBMe preferentially recognize these less ordered regions. In total, these data suggest some differences in the relative affinity and tolerance of the various CBMs towards  $\alpha$ 1,6 branch points in starch, and likely help the enzyme recognize a variety of starch particles in the gut environment. As expected, none of the CBMs demonstrated binding to dextran (data not shown), an all  $\alpha$ -1,6 polymer of glucose on which Amy13K lacks activity.

ITC was also utilized to determine the affinity of the CBMs to glycogen, maltoheptaose and  $\beta$ cyclodextrin. Glycogen is a starch-like storage molecule in many animals and bacteria, and it is structurally similar to amylopectin with an increased  $\alpha$ 1,6-branch frequency making it much more soluble and thus easily used in ITC. Maltoheptaose represents a stretch of  $\alpha$ -1,4 linked glucose with flexible geometry and typically longer than the binding surface of CBMs, while  $\beta$ -cyclodextrin is identical in composition to maltoheptaose but circular, with a curvature matching that seen in amylose (Imberty et al., 1991). All of the CBM constructs tested exhibited binding to each of these ligands (Table 2), with varying affinity. For the oligosaccharides most constructs displayed similar affinity for maltoheptaose and  $\beta$ -cyclodextrin with  $K_d$  in the 10<sup>-3</sup> to 10<sup>-4</sup> M range, somewhat weaker than has previously been observed in CBM26 at 10<sup>-5</sup> M (Boraston *et al.*, 2006) and CBM41 at 10<sup>-6</sup> M (Lammerts van Bueren et al., 2004a), though this latter was derived from a thermophile which may explain the tighter binding at room temperature. Interestingly the CBMde construct had a  $K_d$  for maltoheptaose approximately an order of magnitude lower than that for  $\beta$ -cyclodextrin. This is consistent with increased affinity for binding near branch points where the helical structure of the starch is disrupted, and in line with our affinity electrophoresis data. The longer constructs, CBMb-e and CBMa-e each displayed higher affinity for the oligosaccharides than the smaller constructs. As we do not expect cooperativity in the binding of these substrates nor do we expect the substrates to span multiple CBMs, we speculate that improved structural stability in the larger constructs may be responsible for this enhanced affinity. With glycogen, the individual constructs CBMa and CBMe display binding with  $K_d$ 

### This article is protected by copyright. All rights reserved.

~10<sup>-4</sup> M, and this is enhanced an order of magnitude ( $K_d$  ~10<sup>-5</sup> M) when two CBMs such CBMbc or CBMde are expressed in tandem. Glycogen binding is further enhanced an additional two orders of magnitude ( $K_d \sim 10^{-7}$  M) when four or five CBMs are expressed in tandem as in CBMa-e and CBMb-e, demonstrating that there is a significant avidity effect from having multiple CBMs. When considering the binding of CBMs to a polysaccharide it is not just the affinity, but also the frequency of binding sites that is important. Not surprisingly the single CBM constructs have a relatively high frequency of binding sites in glycogen (Table 2, values in parentheses) with CBMa displaying a binding site frequency of 2.3 mM/% glycogen, while CBMe is somewhat lower at 0.8 mM/% glycogen. Interestingly the dual CBM constructs diverge significantly in this regard with CBMbc displaying a binding site frequency of only 0.05 mM/% glycogen, while CBMde is at 2.4 mM/% glycogen, despite the similar affinities of these two constructs for glycogen. This higher frequency for binding sites for CBMde may suggest that these CBMs have a greater tolerance for the frequent  $\alpha$ -1,6 branch points in glycogen in line with its greater affinity for pullulan in the AE gels (Fig 4). The longer constructs CBMb-e and CBMa-e seem to be limited by the CBMbc binding restrictions as they display similar binding site frequencies at 0.06 mM/% glycogen and 0.1 mM/% glycogen, respectively, though with significantly better affinities. Thus the combination of these CBMs provides high affinity binding, but perhaps at the cost of less frequent binding sites. Furthermore this appears to be driven not just by avidity effects and size of the construct, but also by differing binding specificities.

# Binding of CBMs to granular starch

In complement to binding studies with soluble substrates, the ability to interact with granular starch, which represents some of the starch that would be expected to traverse the distal gut, was investigated. In these adsorption assays, proteins and starch were incubated followed by centrifugation to determine the remaining concentration of unbound protein. Binding of the CBM

constructs to standard cornstarch, whole grain corn starch, a high amylose corn starch (HiMaize 260), potato starch, and the chemically modified resistant starch Fibersym was tested (Table 3). No binding was detected for whole grain corn starch (data not shown) likely because the starch itself is inaccessible due to the presence of the bran, making it a type-1 resistant starch (Birt et al., 2013). It has not been tested if whole grain starch serves as a growth substrate for *E. rectale*, but this result suggests it is unlikely. Significant binding towards Fibersym was only evident for the CBMa-e, and CBMb-e constructs, suggesting that no single CBM domain drives affinity, rather avidity from multiple domains is required. With regular corn starch, similar binding was observed among the CBMa and CBMde constructs, while CBMbc displays ~3-fold lower affinity. The pairing of these CBMs together in the longer constructs CBMa-e and CBMb-e did not significantly enhance binding, suggesting avidity is not as important for access to corn starch. However, for the high-amylose starch HiMaize260, the longer CBMa-e and CBMb-e constructs displayed 3-10-fold enhanced affinity over the smaller constructs. Surprisingly, the CBMa-e construct on average had lower affinity than the construct lacking only CBMa, despite the fact that CBMa binds HiMaize with similar affinity to the CBMbc and CBMde constructs. Thus Amy13K CBMs seem to recognize high-amylose and mixed amylopectin/amylose corn starches with similar affinities. This was consistent across most of the CBM constructs tested, suggesting that these two forms of corn starch present similar binding surfaces to Amy13K.

Interestingly, the CBMs of Amy13K do not appreciably bind potato starch, with only slight binding observed for the largest CBM construct, and binding was not saturable. Relatively few studies have examined the difference in binding between corn starch and potato starch for amylolytic CBMs, though both the pig pancreatic amylase (Warren *et al.*, 2011) and the barley α-amylase AMY1 (Cockburn *et al.*, 2015a) have surface binding sites that seem to preferentially bind corn starch over potato starch. One interesting study found that for the *A. niger* CBM20 the affinity for potato starch and corn starch binding sites available on the

### This article is protected by copyright. All rights reserved.

potato starch, resulting in a much lower apparent affinity (Paldi *et al.*, 2003). One point to note is that the approximately 7-fold difference in CBM20 binding sites in this study is significantly larger than the ~3-fold difference in specific surface area between these two starch types (Warren *et al.*, 2011). This indicates that it is not just the size of the surface available for binding that differs, but also the frequency of structural binding motifs. Binding to the surface of starch granules is an important barrier to enzyme action as the granule interiors seem to be readily attacked (Gallant *et al.*, 1992), even by enzymes lacking CBMs or surface binding sites (Cockburn *et al.*, 2015a). Removal of the CBM(s) of the *Microbacterium aurum*  $\alpha$ -amylase MaAmyA removed the ability of the enzyme to form pores in starch granules (Valk *et al.*, 2015). Interestingly, it was discovered that this enzyme possesses a novel type of CBM, which was assigned to the new CBM74 family (Valk *et al.*, 2016). This CBM is of particular interest as it displays a 10-fold better affinity for potato starch compared to corn starch and is enriched in gut bacteria, particularly resistant starch degraders such as a variety of *Bifidobacterium* species and *R*. *bromii*. Thus acquiring novel binding functionalities may be a key adaptation of potato starch-degrading organisms.

### Activity of Amy13K and CBM truncation mutants

To probe the role of these CBMs on enzyme activity, the activity of the full-length (WT) enzyme was compared to that of truncation mutants lacking one, three or all five of the identified CBMs (Fig 1). In preliminary tests, constructs lacking three or all five CBMs displayed greatly reduced activity such that substrate saturation could not be attained, even when pushed to the maximum feasible levels. In addition, none of the enzyme constructs exhibited saturation kinetics for the potato starch. Therefore we compared the catalytic efficiency ( $k_{cat}/K_{M}$ ) of these constructs to focus on the role of these CBMs on starch hydrolysis.

To examine if removal of the CBMs affected activity of the enzyme overall, we measured the catalytic efficiency of the WT and  $\Delta$ CBMa-e on maltoheptaose, as hydrolysis of this small substrate would not be subject to an avidity affect via the CBMs. The catalytic efficiency of the WT and ΔCBMa-e on maltoheptaose are 2.8  $\times 10^4 \pm 1.9 \times 10^4 \text{ s}^{-1} \text{ M}^{-1}$  and 1.2  $\times 10^4 \pm 8.6 \times 10^3 \text{ s}^{-1} \text{ M}^{-1}$  respectively, suggesting that these truncated constructs have a slightly lower inherent activity as it is unclear how the CBMs could contribute to activity on a small substrate. However, with soluble starch amylopectin, the same 2-3-fold decrease in catalytic efficiency between the full-length enzyme and the constructs lacking various CBMs was observed, suggesting the CBMs are not required to enhance access to this substrate (Table 4). This is despite the efficient binding of these CBMs to the similar substrate (Table 2), suggesting a high affinity of the enzyme active site for amylopectin that is not further enhanced by the CBMs. Intriguingly, activity levels were similar for each construct towards both regular and high-amylose corn starch granules. This is in line with the binding assays for these substrates, and may suggest that the initial surface presented to the enzyme by these substrates is similar. For both regular and HiMaize corn starch there is a significantly higher dependence on the CBMs with the activity decreasing by an order of magnitude as the CBMs are removed. In contrast the potato starch, which has a low dependence on the CBMs, displayed an approximately 3-fold decrease in activity for the  $\Delta$ CBMa-e enzyme compared to the WT enzyme. Most strikingly the enzymes lacking 3 or all 5 of the CBMs show similar activity towards the three insoluble starches, while the full length enzyme shows a much more dramatic decrease in catalytic efficiency between the corn starches and the potato starch.

Potato starch adopts the B-type crystalline form, as opposed to the A-type form seen in most corn and wheat starches (Imberty *et al.*, 1991). High amylose corn starch such as the HiMaize 260 used in this study also adopts the B-type crystalline form and this may explain its resistance to degradation (Gallant *et al.*, 1992). Interestingly the Amy13K CBMs bind similarly to both regular corn starch and HiMaize260 and the enzyme exhibits similar activity towards the two substrates. This indicates that surface binding

does not represent the barrier to efficient degradation (and hence growth) in this case as it does with potato starch. It should be noted that the activities measured in this study only represent the initial stages of degradation that occurs on the granule surface. It is possible that the total amount of starch susceptible to degradation by Amy13K is much smaller for HiMaize260 compared to regular corn starch, once the granule surface has been degraded.

One final construct was tested where all the identified CBMs as well as an additional ~200 amino acids that occur between the CBMs and the predicted start of the GH13 catalytic domain, labeled as the unknown region in Fig 1, were removed. While we were able to obtain large amounts of this recombinant protein in a soluble form during expression in *E. coli*, it had no detectable activity, even towards soluble substrates and oligosaccharides. Secondary structure predictions (JPred4, http://www.compbio.dundee.ac.uk/jpred/) (Drozdetskiy *et al.*, 2015) do not indicate β-strand rich regions as are typically found in CBMs and there are no domains with ascribed function that match this sequence. However, this region clearly plays an important structural role in Amy13K, perhaps directly

impacting the active site.

#### Discussion

### Importance of CBMs for activity

It has been demonstrated that CBMs are important for targeting substrates in complex environments such as the plant cell wall (Hervé *et al.*, 2010) and undoubtedly the breakdown of starch in the gut provides similar challenges. During *in vitro* studies the removal of a starch binding CBM20 abolished activity of the *Aspergillus niger* glucoamylase towards granular starch (Svensson *et al.*, 1982). Conversely, recombinantly fusing this CBM20 to the barley  $\alpha$ -amylase AMY1 increased its activity towards granular starch 6-fold (Juge *et al.*, 2006). This is despite the fact that AMY1, while lacking a CBM, has a pair of surface binding sites on its catalytic module, which have been shown to be

important for its activity (Cockburn *et al.*, 2015a, Nielsen *et al.*, 2009, Nielsen *et al.*, 2012). In Amy13K we have identified five CBMs that provide the enzyme with affinity for starch granules. Removal of these CBMs has little impact on the activity of the enzyme towards maltoheptaose or soluble amylopectin, but has a more dramatic effect on the activity towards cornstarch granules. Notably this difference disappears when examining activity towards potato starch, for which the CBMs have apparently less affinity. The protein lacking all five CBMs displays little discrimination between the three types of insoluble starches tested, suggesting that the CBMs account for the differences in activity against these substrates. The lower activity and lack of dependence on the CBMs for potato starch corresponds to the lack of binding seen for the isolated CBMs.

### Implications for relationships with other gut microorganisms

Resistant starch represents an important substrate for the gut microbiota, while non-resistant starch is processed in the small intestine and thus does not reach the microbial populations of the large intestine. Potato and high amylose corn starch consist of about 40-80% resistant starch (depending on the specific type and method of measurement used) (McCleary & Monaghan, 2002) and thus a large proportion of these starches reach the colon. *E. rectale* alone is unable to grow on resistant starches, but grows well in co-culture with resistant starch degraders such as *Ruminococcus bromii* (Ze *et al.,* 2012). Our results suggest that for potato starch it is the lack of efficient targeting by the CBMs of Amy13K that underpins the molecular basis for *E. rectale*'s inability to grow on this substrate. This inefficient targeting seems to be entirely due to the granular structure of potato starch as purified and autoclaved potato amylopectin readily supports growth of *E. rectale* (Desai *et al.,* 2016) and is efficiently bound by the Amy13K CBMs (Fig 4).

Despite its limited ability to grow on resistant starches, people who consume resistant starch often have increased levels of *E. rectale* in their large intestine (Martínez *et al.*, 2010, Martínez *et al.*, 2013,

Venkataraman et al., 2016). While E. rectale has a suite of transporters specializing in the uptake of starch breakdown products (Cockburn et al., 2015b), it would clearly be advantageous for the organisms to localize to this food source. E. rectale lacks accessory starch binding proteins such as those found in the starch utilization system (Sus) of Bacteroides thetaiotaomicron (Cameron et al., 2012, Foley et al., 2016). Instead it is possible that the CBMs of the cell wall anchored Amy13K help localize the bacteria to resistant starches such as high amylose corn starch. Indeed E. rectale was found to colonize high amylose corn starch in an in vitro continuous flow system (Leitch et al., 2007). E. rectale levels are enriched upon diet supplementation with potato starch (Venkataraman et al., 2016), but given the lack of binding to this starch by the Amy13K CBMs other means of localization may be needed or it is possible that enough soluble material is released by degraders to render binding to potato starch granules unnecessary. However, the affinity of these CBMs for potato amylopectin may indicate that upon initial processing of potato starch, new binding sites are opened up for binding by Amy13K. The Amy13K CBMs do display weak binding to Fibersym, a Type IV, chemically modified resistant starch, however, a study with people consuming this starch did not find elevated levels of E. rectale (Martínez et al., 2010). It is also currently unknown if this starch can directly support E. rectale growth or indirectly through cross-feeding with a primary degrader.

# Conclusion

We have identified and characterized the five CBMs of Amy13K, which allow the definition of two new CBM families. These CBMs bind efficiently to corn starch, including high amylose corn starch as well as amylopectin and maltooligosaccharides, but display little affinity for potato starch. The low affinity of these CBMs for granular potato starch may be a key factor in the low activity of Amy13K for this substrate and provides a molecular rationale for why this is a poor growth substrate for *E. rectale*. In contrast it seems that other factors are at play in limiting the ability of *E. rectale* to utilize high amylose

corn starch as the surface binding and initial rates of degradation are similar to regular corn starch. It could be that following the initial surface erosion the binding motifs recognized by the Amy13K CBMs are eliminated decreasing affinity and activity to that seen with potato starch. Indeed, in previous work examining the ability of *E. rectale* to utilize corn starches, the bacterium can utilize less than 20% of high amylose corn starch when cultured with the raw granules that have not been heat treated (Ze *et al.*, 2012). Our results presented here provide important insight into the potential roles of CBMs in determining substrate utilization profiles in the human gastrointestinal tract.

### **Experimental procedures**

Reagents

Primers used for cloning were synthesized by IDT DNA Technologies and are listed in Table S1. HiMaize260 starch and whole grain starch were kindly provided by Ingredion (Bridgewater, NJ, USA). FiberSym starch (MGP Ingredients) was a gift from Jens Walter (University of Alberta, Canada). All other chemicals were purchased from Sigma Aldrich, except where noted.

### Cloning, protein expression and purification

All genes and gene fragments were amplified from *E. rectale* genomic DNA using the Phusion<sup>™</sup> Flash polymerase (Thermo Fisher Scientific) according to the manufacturer's instructions and all primer sequences are listed in Table S1. All genetic constructs used in this study were created using the Expresso® T7 Cloning system (Lucigen Inc.) according to the manufacturer's instructions and are listed in Table S2. Expression plasmids were transformed into *E. coli* Rosetta(DE3) pLysS cells, expressed and purified as previously described (Cockburn *et al.*, 2015b). Selenomethionine substituted Amy13K\_CBMbc was produced by first transforming the plasmid into *E. coli* Rosetta(DE3)/pLysS and plating onto LB supplemented with kanamycin (50 µg/ml) and chloramphenicol (20 µg/ml). The bacteria were grown for 16 h at 37°C and then colonies were harvested from the plate to inoculate 100 mL of M9 minimal medium supplemented with the same antibiotics. After 16 h of incubation at 37 °C this starter culture was used to inoculate a 2-liter baffled flask containing 1 liter of Molecular Dimensions SelenoMet premade medium supplemented with 50 ml of the recommended sterile nutrient mix, chloramphenicol, and kanamycin. Cultures were incubated at 37°C until an OD<sub>600</sub> of 0.45 was reached. At this point the temperature was adjusted to 20°C and each flask was supplemented with 100 mg each of L-lysine, L-threonine, and L-phenylalanine and 50 mg each of L-leucine, L-isoleucine, L-valine, and L-selenomethionine (Van Duyne *et al.*, 1993). After 20 min of further incubation, protein expression was induced by the addition of 0.5 mM IPTG and cultures were allowed to grow for an additional 48 h before being harvested. Cells were then lysed and the protein purified as previously described via Ni<sup>2+</sup> affinity chromatography (Cockburn *et al.*, 2015b).

# Crystallization experiments

All proteins were subjected to a series of 96-well hanging drop sparse matrix screens to identify crystallization conditions. Selenomethionine-substituted crystals of Amy13k\_CBMbc (54 mg/ml) were obtained via hanging drop vapor diffusion at room temperature against 1.5 M ammonium sulfate, 0.1 M Bis-Tris Propane, pH 7.0 (Hampton Research SaltRx). Native Amy13K\_CBMbc crystals were obtained without (free) or with 14mM maltoheptaose via hanging drop experiments against 60% Tacsimate, 0.1 M Bis-Tris Propane, pH 7.0 (Hampton Research SaltRx), also at room temperature. Native Amy13K\_CBMd crystals were obtained via hanging drop against 50% pentaerythritol propoxylate (5/4 PO/OH), 0.1 M Tris-HCl pH 8.0 in the Molecular Dimensions Midas screen using 20 mg/mL protein. All crystals used in this study were cryoprotected prior to freezing in liquid nitrogen by quickly swiping the crystal through a solution of 80% mother liquor supplemented with 20% ethylene glycol. X-ray data were collected at the Life Sciences Collaborative Access Team (LSCAT) beamline ID-D of the Advanced

Photon Source at Argonne National Laboratory. Data were integrated using iMosFLM (Battye *et al.*, 2011) and then indexed and scaled using the program Aimless (Evans & Murshudov, 2013) from the CCP4 package (Winn *et al.*, 2011). For the selenomethionine substituted Amy13K\_CBMbc, phases were solved by single anomalous dispersion (SAD) using the AutoSol program of the Phenix package (Adams *et al.*, 2010). This structure was then used to solve the native Amy13K\_CBMbc with or without maltoheptaose by molecular replacement using Phaser-MR (McCoy *et al.*, 2007) within Phenix. In the substrate free structure, four molecules were found in the asymmetric unit, however, chain D exhibited higher mobility than the other chains and not all amino acid sidechains from Y297-I356 could be confidently fit to the electron density and were thus omitted. The Amy13K\_CBMd structure was solved via sulfur SAD after merging seven datasets from three crystals with autoPROC (Vonrhein *et al.*, 2011) and phasing in AutoSol. The resulting structure was then used to solve the structure from a single dataset via molecular replacement with Phaser-MR. Structures were refined using Phenix.refine (Afonine *et al.*, 2012). In the maltoheptaose bound structure of Amy13K\_CBMbc the conformation of bound carbohydrates was validated using Privateer (Agirre *et al.*, 2015) from the CCP4 package.

### Enzyme activity assays

For activity assays with polysaccharide substrates the production of free reducing ends was monitored using the bicinchoninic acid (BCA) method (Waffenschmidt & Jaenicke, 1987) as previously described (Cockburn *et al.*, 2015b). All reactions included 10 mM HEPES pH 6.5, with 5 mM CaCl<sub>2</sub> and 0.02% Tween80. All granular starch substrates were washed 10x in pure water prior to activity assays. For activity towards amylopectin Amy13K\_WT (2.2 nM),  $\Delta$ CBMa (2.4 nM),  $\Delta$ CBMa-c (3.0 nM) or  $\Delta$ CBMa-e (4.0 nM) was incubated with six concentrations of potato amylopectin (0.003 – 0.5%). Reactions were monitored for 30 min. Initial velocities were calculated and fitted to a Michalis-Menten curve to calculate  $k_{cat}$  and  $K_{M}$ . For activity towards corn starch Amy13K\_WT (3 nM),  $\Delta$ CBMa (6 nM),  $\Delta$ CBMa-c (15

nM) or  $\Delta$ CBMa-e (26 nM) were incubated with six concentrations of granular corn starch (0.2 – 10%) and activity was monitored for 135 min. Initial velocities were plotted against substrate concentration and for WT and  $\Delta$ CBMa the  $k_{cat}$  and  $K_{M}$  were derived through fitting to a Michalis-Menten curve. For  $\Delta$ <u>CBMa-c and</u>  $\Delta$ CBMa-e it was only possible to derive  $k_{cat}/K_{M}$  from the slope of the line. For activity towards HiMaize 260 starch, Amy13K\_WT (4 nM), ΔCBMa (8 nM), ΔCBMa-c (20 nM) or ΔCBMa-e (40 nM) were incubated with six concentrations of granular HiMaize 260 high amylose corn starch (0.06 – 6%) and activity was monitored for 135 min. Initial velocities were plotted against substrate concentration and for WT and  $\Delta$ CBMa the  $k_{cat}$  and  $K_{M}$  were derived through fitting to a Michalis-Menten curve. For  $\Delta$ CBMa-c and  $\Delta$ CBMa-e it was only possible to derive  $k_{cat}/K_{M}$  from the slope of the line. For activity towards potato starch, Amy13K WT (1.1 nM), ΔCBMa (1.2 nM), ΔCBMa-c (1.5 nM) or ΔCBMa-e (2.0 nM) were incubated with six concentrations of granular potato starch (Bob's RedMill; 0.5 - 20%). Initial velocities were plotted against substrate concentration and  $k_{cat}/K_{M}$  was calculated from the slope of the line. Activity towards oligosaccharides was monitored via isothermal titration calorimetry. Amv13K WT (11 nM) or ΔCBMa-e (20 nM) were placed into the cell of a standard volume Nano ITC (TA Instruments, New Castle, Delaware). 40 mM maltoheptaose was serially injected into the cell while stirring at 350 RPM at a temperature of 37 °C (see Table S3 for injection volumes and times). The molecular enthalpy of the reaction was calculated to be 4.41 kJ/mol by monitoring the complete conversion of 10 mM maltotetraose to maltose by 8 mg/mL Amy13B, formerly EUR 01860 (Cockburn et al., 2015b) in duplicate, which agreed well with previous estimates (Goldberg et al., 1991). Catalytic parameters were determined using the NanoAnalyze software (TA instruments).

### Isothermal titration calorimetry CBM binding assays

CBM binding to maltoheptaose,  $\beta$ -cyclodextrin and glycogen was determined by isothermal titration calorimetry (ITC) using a TA Instruments low volume NanoITC. For CBMa, 63  $\mu$ M protein was titrated

with 10 and 13 mM  $\beta$ -cyclodextrin, 20 mM maltoheptaose or 1% and 2% glycogen (MW ~10<sup>6</sup>-10<sup>7</sup>, from rabbit liver). CBMbc was used at a concentration of 42  $\mu$ M and titrated with 10 mM  $\beta$ -cyclodextrin, 10 and 25 mM maltoheptaose or 5% glycogen. The CBMde construct was used at a concentration of 190  $\mu$ M and titrated with 1 mM and 5 mM maltoheptaose, 2.5 mM  $\beta$ -cyclodextrin or 1%, 1.5% and 2% glycogen. CBMe was measured at 780  $\mu$ M and titrated with 10 mM and 13 mM  $\beta$ -cyclodextrin, 20 mM maltoheptaose or 5% and 10% glycogen. CBMb-e was measured at 5  $\mu$ M and titrated with 4 and 5 mM  $\beta$ -cyclodextrin, 20 mM maltoheptaose or 0.5% and 1% glycogen. CBMa-e was measured at 7.8  $\mu$ M and titrated with 2 or 4 mM  $\beta$ -cyclodextrin, 5 mM maltoheptaose or 1% and 2% glycogen. All data were analyzed using the manufacturer's NanoAnalyze software, using a constant blank correction and an independent binding model unless otherwise noted. To obtain  $K_d$  values it was necessary to fix the value of n (number of binding sites) in these calculations. For maltoheptaose and  $\beta$ -cyclodextrin the value of n was fixed at the number of CBMs in the construct (e.g. 1 for CBMa, 2 for CBMbc). For glycogen the molar concentration of the ligand used was empirically set such that it produced a value for n of 1 when fitting the curve to the data. Thus the concentration of glycogen used in this calculation represents the molar concentration of available binding sites on the polysaccharide ligand, according to the protocol of Abbott et al. (Abbott & Boraston, 2012). The binding site frequency (mM/% glycogen) for each construct was calculated as the slope of the concentration of binding sites over the w/v% of glycogen used. For example the CBMb-e construct was assayed for binding at 0.5% and 1% glycogen. The binding site concentration (the concentration found to give n=1 during curve fitting) was 0.022 mM and 0.05 mM respectively. Calculating the slope (0.05 - 0.022)/(1 - 0.5) gives a binding site frequency of 0.056 mM/%glycogen (rounded to 0.06 in Table 2). This represents the concentration of binding sites for a particular construct, *i.e.* how many copies can bind before reaching saturation for 1% w/v glycogen. Thus we would expect lower numbers for larger constructs (each takes up more space) and for constructs that have a relatively infrequently occurring binding motif.

#### Starch binding assays

Binding of isolated CBMs to insoluble corn starch, whole grain starch, HiMaize 260 high amylose starch, potato starch or Fibersym chemically modified resistant starch was determined through protein depletion assays (Abbott & Boraston, 2012). Prior to protein addition, the starch was washed two times with 10 mM HEPES pH 6.5, 150 mM NaCl. CBMs (80 µg/mL) were then incubated with 1-100 mg/mL starch for 10 min at room temp with end-over-end rotation and insoluble material (including bound protein) was removed by two rounds of centrifugation at 20 000 xg. Protein concentration in the supernatant (unbound) was then determined by the Bradford assay (Bio-Rad) according to the manufacturer's protocol, using the CBM construct under study as the protein standard. The fraction of protein bound to starch was then plotted against starch concentration to determine binding constants using the following formula:

$$B = \frac{B_{max}[S]}{K_{d} + [S]}$$

Where *B* is the fraction of protein bound,  $B_{max}$  is the maximum proportion of protein bound, [S] is the concentration of starch and  $K_d$  is the dissociation constant.

# Affinity electrophoresis

To investigate binding of CBMs to amylose, amylopectin, glycogen, pullulan and dextran, affinity electrophoresis was used (Abbott & Boraston, 2012, Cockburn *et al.*, 2017). Native polyacrylamide gels with and without added polysaccharide were compared for each CBM construct. Binding was considered positive if the migration of the protein in the polysaccharide gel relative to a non-interacting protein (bovine serum albumin) was significantly slower (<0.85 relative mobility) compared to that in the control gel. All polysaccharides were used at 0.1% final concentration. Gels were made at 12% acrylamide with 0.375 M Tris-HCl pH 8.8. Gels were subjected to 100 V for 4 h and then stained for

2 h with 0.1% Coomassie Brilliant Blue R-250 in 10% acetic acid, 50% methanol, 40% water, before destaining with solution lacking Coomassie overnight with one change of solution.

# Bioinformatic analysis

The boundaries of the CBMs were determined from examination of the 3-D structures. The sequence corresponding to each CBM was compared to the sequences of the CBM families listed in the CAZy database using BLAST (Altschul *et al.*, 1990).

# Acknowledgements

This work was supported by funds from a pilot/feasibility grant from the University of Michigan Gastrointestinal Peptides Research Center (DK034933) awarded to N.M.K. and a scientist development grant from the American Heart Association (17SDG32770001) to D.W.C. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract no. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (grant 085P1000817).

# **Author Contributions**

The study was designed by D.W.C. and N.M.K. Data were collected by D.W.C., C.S., K.P.M., and B.M.D., and analyzed by D.W.C, N.M.K. and B.H. Sequence alignments and CBM classification was performed by B.H. X-ray data was collected and processed by D.W.C. and Z.W. The manuscript was written by D.W.C. and N.M.K.

### References

Abbott, D.W. & A.B. Boraston, (2012) Quantitative approaches to the analysis of carbohydrate-binding module function. *Methods in Enzymology* **510**: 211-231.

Adams, P.D., P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.-W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger & P.H. Zwart, (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**: 213-221.

Afonine, P.V., R.W. Grosse-Kunstleve, N. Echols, J.J. Headd, N.W. Moriarty, M. Mustyakimov, T.C. Terwilliger, A. Urzhumtsev, P.H. Zwart & P.D. Adams, (2012) Towards automated crystallographic structure refinement with phenix.refine. *Acta crystallographica. Section D, Biological crystallography* **68**: 352-367.

Agirre, J., J. Iglesias-Fernandez, C. Rovira, G.J. Davies, K.S. Wilson & K.D. Cowtan, (2015) Privateer: software for the conformational validation of carbohydrate structures. *Nat Struct Mol Biol* **22**: 833-834.

Altschul, S.F., W. Gish, W. Miller, E.W. Myers & D.J. Lipman, (1990) Basic local alignment search tool. *Journal of Molecular Biology* **215**: 403-410.

Battye, T.G.G., L. Kontogiannis, O. Johnson, H.R. Powell & A.G.W. Leslie, (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. *Acta Crystallographica Section D* **67**: 271-281.

Beauvieux, M.C., H. Roumes, N. Robert, H. Gin, V. Rigalleau & J.L. Gallis, (2008) Butyrate ingestion improves hepatic glycogen storage in the re-fed rat. *BMC physiology* **8**: 19.

Berggren, A.M., E.M. Nyman, I. Lundquist & I.M. Bjorck, (1996) Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. *The British journal of nutrition* **76**: 287-294.

Birt, D.F., T. Boylston, S. Hendrich, J.-L. Jane, J. Hollis, L. Li, J. McClelland, S. Moore, G.J. Phillips, M. Rowling, K. Schalinske, M.P. Scott & E.M. Whitley, (2013) Resistant starch: promise for improving human health. *Advances in Nutrition* **4**: 587-601.

Boets, E., S.V. Gomand, L. Deroover, T. Preston, K. Vermeulen, V. De Preter, H. Hamer, G. Van den Mooter, L. De Vuyst, C.M. Courtin, P. Annaert, J.A. Delcour & K.A. Verbeke, (2016) Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects - a stable isotope study. *The Journal of physiology*.

Boraston, A.B., M. Healey, J. Klassen, E. Ficko-Blean, A. Lammerts van Bueren & V. Law, (2006) A structural and functional analysis of  $\alpha$ -glucan recognition by family 25 and 26 carbohydrate-binding modules reveals a conserved mode of starch recognition. *The Journal of biological chemistry* **281**: 587-598.

Bruzzese, E., M.L. Callegari, V. Raia, S. Viscovo, R. Scotto, S. Ferrari, L. Morelli, V. Buccigrossi, A. Lo Vecchio, E. Ruberto & A. Guarino, (2014) Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and Its restoration with *Lactobacillus* GG: a randomised clinical trial. *PloS one* **9**: e87796.

Cameron, E.A., M.A. Maynard, C.J. Smith, T.J. Smith, N.M. Koropatkin & E.C. Martens, (2012) Multidomain carbohydrate-binding proteins involved in Bacteroides thetaiotaomicron starch metabolism. *The Journal of biological chemistry* **287**: 34614-34625.

Cockburn, D., M.M. Nielsen, C. Christiansen, J.M. Andersen, J.B. Rannes, A. Blennow & B. Svensson, (2015a) Surface binding sites in amylase have distinct roles in recognition of starch structure motifs and degradation. *International Journal of Biological Macromolecules* **75**: 338-345.

Cockburn, D. & B. Svensson, (2016) Structure and functional roles of surface binding sites in amylolytic enzymes. In: Understanding Enzymes: Function, Design, Engineering and Analysis. Pan Stanford Publishing Pte. Ltd., pp. 267-295.

Cockburn, D., C. Wilkens & B. Svensson, (2017) Affinity Electrophoresis for Analysis of Catalytic Module-Carbohydrate Interactions. *Methods in molecular biology (Clifton, N.J.)* **1588**: 119-127.

Cockburn, D.W., N.I. Orlovsky, M.H. Foley, K.J. Kwiatkowski, C.M. Bahr, M. Maynard, B. Demeler & N.M. Koropatkin, (2015b) Molecular details of a starch utilization pathway in the human gut symbiont *Eubacterium rectale. Molecular microbiology* **95**: 209-230.

Dais, P., S. Vlachou & F.R. Taravel, (2001) (13)C nuclear magnetic relaxation study of segmental dynamics of the heteropolysaccharide pullulan in dilute solutions. *Biomacromolecules* **2**: 1137-1147.

Damager, I., S.B. Engelsen, A. Blennow, B.L. Møller & M.S. Motawia, (2010) First principles insight into the  $\alpha$ -glucan structures of starch: their synthesis, conformation, and hydration. *Chemical Reviews* **110**: 2049-2080.

De Cruz, P., S. Kang, J. Wagner, M. Buckley, W.H. Sim, L. Prideaux, T. Lockett, C. McSweeney, M. Morrison, C.D. Kirkwood & M.A. Kamm, (2015) Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study. *Journal of gastroenterology and hepatology* **30**: 268-278.

Desai, M.S., A.M. Seekatz, N.M. Koropatkin, N. Kamada, C.A. Hickey, M. Wolter, N.A. Pudlo, S. Kitamoto, N. Terrapon, A. Muller, V.B. Young, B. Henrissat, P. Wilmes, T.S. Stappenbeck, G. Nunez & E.C. Martens, (2016) A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. *Cell* **167**: 1339-1353.e1321.

Drozdetskiy, A., C. Cole, J. Procter & G.J. Barton, (2015) JPred4: a protein secondary structure prediction server. *Nucleic acids research* **43**: W389-394.

Evans, P.R. & G.N. Murshudov, (2013) How good are my data and what is the resolution? *Acta crystallographica*. *Section D, Biological crystallography* **69**: 1204-1214.

Foley, M.H., D.W. Cockburn & N.M. Koropatkin, (2016) The Sus operon: a model system for starch uptake by the human gut Bacteroidetes. *Cellular and molecular life sciences : CMLS* **73**: 2603-2617.

Forslund, K., F. Hildebrand, T. Nielsen, G. Falony, E. Le Chatelier, S. Sunagawa, E. Prifti, S. Vieira-Silva, V. Gudmundsdottir, H. Krogh Pedersen, M. Arumugam, K. Kristiansen, A. Yvonne Voigt, H. Vestergaard, R. Hercog, P. Igor Costea, J. Roat Kultima, J. Li, T. Jorgensen, F. Levenez, J. Dore, H. Bjorn Nielsen, S.

Brunak, J. Raes, T. Hansen, J. Wang, S. Dusko Ehrlich, P. Bork & O. Pedersen, (2015) Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature*.

Fung, K.Y.C., L. Cosgrove, T. Lockett, R. Head & D.L. Topping, (2012) A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. *Brit J Nutr* **108**: 820-831.

Gallant, D.J., B. Bouchet, A. Buleon & S. Perez, (1992) Physical characteristics of starch granules and susceptibility to enzymatic degradation. *European journal of clinical nutrition* **46 Suppl 2**: S3-16.

Goldberg, R.N., D. Bell, Y.B. Tewari & M.A. McLaughlin, (1991) Thermodynamics of hydrolysis of oligosaccharides. *Biophysical chemistry* **40**: 69-76.

Gossling, J. & J.M. Slack, (1974) Predominant Gram-positive bacteria in human feces: numbers, variety, and persistence. *Infection and Immunity* **9**: 719-729.

Guilloteau, P., L. Martin, V. Eeckhaut, R. Ducatelle, R. Zabielski & F. Van Immerseel, (2010) From the gut to the peripheral tissues: the multiple effects of butyrate. *Nutrition research reviews* **23**: 366-384.

Haro, C., S. Garcia-Carpintero, J.F. Alcala-Diaz, F. Gomez-Delgado, J. Delgado-Lista, P. Perez-Martinez, O.A. Rangel Zuniga, G.M. Quintana-Navarro, B.B. Landa, J.C. Clemente, J. Lopez-Miranda, A. Camargo & F. Perez-Jimenez, (2016) The gut microbial community in metabolic syndrome patients is modified by diet. *The Journal of nutritional biochemistry* **27**: 27-31.

Hervé, C., A. Rogowski, A.W. Blake, S.E. Marcus, H.J. Gilbert & J.P. Knox, (2010) Carbohydrate-binding modules promote the enzymatic deconstruction of intact plant cell walls by targeting and proximity effects. *Proceedings of the National Academy of Sciences of the United States of America*.

Imberty, A., A. Buléon, V. Tran & S. Pérez, (1991) Recent advances in knowledge of starch structure. *Starch-Stärke* **43**: 375-384.

Janecek, S., K. Majzlova, B. Svensson & E.A. MacGregor, (2017) The starch-binding domain family CBM41-An in silico analysis of evolutionary relationships. *Proteins* **85**: 1480-1492.

Juge, N., J. Nøhr, M.-F. Le Gal-Coëffet, B. Kramhøft, C.S.M. Furniss, V. Planchot, D.B. Archer, G. Williamson & B. Svensson, (2006) The activity of barley  $\alpha$ -amylase on starch granules is enhanced by fusion of a starch binding domain from *Aspergillus niger* glucoamylase. *Biochimica et Biophysica Acta* **1764**: 275-284.

Kang, S., S.E. Denman, M. Morrison, Z. Yu, J. Dore, M. Leclerc & C.S. McSweeney, (2010) Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. *Inflammatory bowel diseases* **16**: 2034-2042.

Koropatkin, N.M., E.C. Martens, J.I. Gordon & T.J. Smith, (2008) Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. *Structure* **16**: 1105-1115.

Lammerts van Bueren, A. & A.B. Boraston, (2007) The structural basis of  $\alpha$ -glucan recognition by a family 41 carbohydrate-binding module from Thermotoga maritima. *Journal of Molecular Biology* **365**: 555-560.

Lammerts van Bueren, A., R. Finn, J. Ausió & A.B. Boraston, (2004a) Alpha-glucan recognition by a new family of carbohydrate-binding modules found primarily in bacterial pathogens. *Biochemistry* **43**: 15633-15642.

Lammerts Van Bueren, A., R. Finn, J. Ausió & A.B. Boraston, (2004b)  $\alpha$ -Glucan recognition by a new family of carbohydrate-binding modules found primarily in bacterial pathogens. *Biochemistry* **43**: 15633-15642.

Leitch, E.C.M., A.W. Walker, S.H. Duncan, G. Holtrop & H.J. Flint, (2007) Selective colonization of insoluble substrates by human faecal bacteria. *Environmental microbiology* **9**: 667-679.

Lombard, V., H. Golaconda Ramulu, E. Drula, P.M. Coutinho & B. Henrissat, (2014) The carbohydrateactive enzymes database (CAZy) in 2013. *Nucleic acids research* **42**: D490-495.

Martínez, I., J. Kim, P.R. Duffy, V.L. Schlegel & J. Walter, (2010) Resistant starches types 2 and 4 have differential effects on the composition of the fecal microbiota in human subjects. *PloS one* **5**: e15046.

Martínez, I., J.M. Lattimer, K.L. Hubach, J.a. Case, J. Yang, C.G. Weber, J.a. Louk, D.J. Rose, G. Kyureghian, D.a. Peterson, M.D. Haub & J. Walter, (2013) Gut microbiome composition is linked to whole grain-induced immunological improvements. *The ISME journal* **7**: 269-280.

McCleary, B.V. & D.A. Monaghan, (2002) Measurement of resistant starch. *Journal of AOAC International* **85**: 665-675.

McCoy, A.J., R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni & R.J. Read, (2007) Phaser crystallographic software. *J Appl Crystallogr* **40**: 658-674.

McNeil, N.I., (1984) The contribution of the large intestine to energy supplies in man. *Amer J Clin Nutr* **39**: 338-342.

Møller, M.S., A. Henriksen & B. Svensson, (2016) Structure and function of  $\alpha$ -glucan debranching enzymes. *Cellular and molecular life sciences : CMLS* **73**: 2619-2641.

Motawia, M.S., I. Damager, C.E. Olsen, B.L. Moller, S.B. Engelsen, S. Hansen, L.H. Ogendal & R. Bauer, (2005) Comparative study of small linear and branched alpha-glucans using size exclusion chromatography and static and dynamic light scattering. *Biomacromolecules* **6**: 143-151.

Nastasi, C., M. Candela, C.M. Bonefeld, C. Geisler, M. Hansen, T. Krejsgaard, E. Biagi, M.H. Andersen, P. Brigidi, N. Ødum, T. Litman & A. Woetmann, (2015) The effect of short-chain fatty acids on human monocyte-derived dendritic cells. *Sci Rep* **5**: 16148.

Nielsen, J.W., B. Kramhøft, S. Bozonnet, M. Abou Hachem, S.L.S. Stipp, B. Svensson, M. Willemoës, B. Kramhoft, S. Bozonnet, M. Abou Hachem, S.L.S. Stipp, B. Svensson & M. Willemoës, (2012) Degradation of the starch components amylopectin and amylose by barley  $\alpha$ -amylase 1: role of surface binding site 2. Archives of biochemistry and biophysics **528**: 1-6.

Nielsen, M.M., S. Bozonnet, E.-S. Seo, J.A. Mótyán, J.M. Andersen, A. Dilokpimol, M. Abou Hachem, G. Gyémánt, H. Naested, L. Kandra, B.W. Sigurskjold & B. Svensson, (2009) Two secondary carbohydrate

binding sites on the surface of barley  $\alpha$ -amylase 1 have distinct functions and display synergy in hydrolysis of starch granules. *Biochemistry* **48**: 7686-7697.

Paldi, T., I. Levy & O. Shoseyov, (2003) Glucoamylase starch-binding domain of Aspergillus niger B1: molecular cloning and functional characterization. *The Biochemical journal* **372**: 905-910.

Prajapati, V.D., G.K. Jani & S.M. Khanda, (2013) Pullulan: an exopolysaccharide and its various applications. *Carbohydrate polymers* **95**: 540-549.

Qin, J., Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J.-M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, S. Li, H. Yang, J. Wang, S.D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen & J. Wang, (2012) A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature* **490**: 55-60.

Rajilic-Stojanovic, M., F. Shanahan, F. Guarner & W.M. de Vos, (2013) Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. *Inflammatory bowel diseases* **19**: 481-488.

Ramsay, A.G., K.P. Scott, J.C. Martin, M.T. Rincon & H.J. Flint, (2006) Cell-associated  $\alpha$ -amylases of butyrate-producing Firmicute bacteria from the human colon. *Microbiology (Reading, England)* **152**: 3281-3290.

Ridaura, V.K., J.J. Faith, F.E. Rey, J. Cheng, A.E. Duncan, A.L. Kau, N.W. Griffin, V. Lombard, B. Henrissat, J.R. Bain, M.J. Muehlbauer, O. Ilkayeva, C.F. Semenkovich, K. Funai, D.K. Hayashi, B.J. Lyle, M.C. Martini, L.K. Ursell, J.C. Clemente, W. Van Treuren, W.A. Walters, R. Knight, C.B. Newgard, A.C. Heath & J.I. Gordon, (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science (New York, N.Y.)* **341**: 1079-1090.

Rios-Covian, D., P. Ruas-Madiedo, A. Margolles, M. Gueimonde, C.G. de Los Reyes-Gavilan & N. Salazar, (2016) Intestinal short chain fatty acids and their link with diet and human health. *Frontiers in microbiology* **7**: 185.

Roediger, W.E., (1980) Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. *Gut* **21**: 793-798.

Shanahan, F., D. van Sinderen, P.W. O'Toole & C. Stanton, (2017) Feeding the microbiota: transducer of nutrient signals for the host. *Gut* **66**: 1709-1717.

Svensson, B., T.G. Svendsen, I. Svendsen, T. Sakai & M. Ottesen, (1982) Characterization of two forms of glucoamylase from *Aspergillus niger*. *Carlsberg Res Comm* **47**: 55.

Tap, J., S. Mondot, F. Levenez, E. Pelletier, C. Caron, J.P. Furet, E. Ugarte, R. Munoz-Tamayo, D.L. Paslier, R. Nalin, J. Dore & M. Leclerc, (2009) Towards the human intestinal microbiota phylogenetic core. *Environmental microbiology* **11**: 2574-2584.

Valk, V., W. Eeuwema, F.D. Sarian, R.M. van der Kaaij & L. Dijkhuizen, (2015) Degradation of granular starch by the bacterium *Microbacterium aurum* Strain B8.A involves a modular  $\alpha$ -amylase enzyme system with FNIII and CBM25 domains. *Applied and environmental microbiology* **81**: 6610-6620.

Valk, V., A. Lammerts van Bueren, R.M. van der Kaaij & L. Dijkhuizen, (2016) Carbohydrate-binding module 74 is a novel starch-binding domain associated with large and multidomain  $\alpha$ -amylase enzymes. *The FEBS journal* **283**: 2354-2368.

Van Duyne, G.D., R.F. Standaert, P.A. Karplus, S.L. Schreiber & J. Clardy, (1993) Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. *Journal of Molecular Biology* **229**: 105-124.

Venkataraman, A., J.R. Sieber, A.W. Schmidt, C. Waldron, K.R. Theis & T.M. Schmidt, (2016) Variable responses of human microbiomes to dietary supplementation with resistant starch. *Microbiome* **4**: 33.

Vonrhein, C., C. Flensburg, P. Keller, A. Sharff, O. Smart, W. Paciorek, T. Womack & G. Bricogne, (2011) Data processing and analysis with the autoPROC toolbox. *Acta crystallographica. Section D, Biological crystallography* **67**: 293-302.

Waffenschmidt, S. & L. Jaenicke, (1987) Assay of reducing sugars in the nanomole range with 2,2'-bicinchoninate. *Anal Biochem* **165**: 337-340.

Wang, H.B., P.Y. Wang, X. Wang, Y.L. Wan & Y.C. Liu, (2012) Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. *Digestive diseases and sciences* **57**: 3126-3135.

Warren, F.J., P.G. Royall, S. Gaisford, P.J. Butterworth & P.R. Ellis, (2011) Binding interactions of  $\alpha$ amylase with starch granules: The influence of supramolecular structure and surface area. *Carbohydrate polymers* **86**: 1038-1047.

Winn, M.D., C.C. Ballard, K.D. Cowtan, E.J. Dodson, P. Emsley, P.R. Evans, R.M. Keegan, E.B. Krissinel, A.G.W. Leslie, A. McCoy, S.J. McNicholas, G.N. Murshudov, N.S. Pannu, E.A. Potterton, H.R. Powell, R.J. Read, A. Vagin & K.S. Wilson, (2011) Overview of the CCP4 suite and current developments. *Acta crystallographica. Section D, Biological crystallography* **67**: 235-242.

Wong, J.M.W., R. de Souza, C.W.C. Kendall, A. Emam & D.J.a. Jenkins, (2006) Colonic health: fermentation and short chain fatty acids. *Journal of clinical gastroenterology* **40**: 235-243.

Zackular, J.P., N.T. Baxter, K.D. Iverson, W.D. Sadler, J.F. Petrosino, G.Y. Chen & P.D. Schloss, (2013) The gut microbiome modulates colon tumorigenesis. *mBio* **4**: e00692-00613.

Ze, X., S.H. Duncan, P. Louis & H.J. Flint, (2012) Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. *The ISME journal* **6**: 1535-1543.



	CBMbc Native	CBMbc M7	CBMd
PDB code	6B15	6B3P	6AZ5
Wavelength	0.979	0.979	0.979
Decel at the second	36.02 - 2.1	28.15 - 2.01	33.28 - 2.2
Resolution range	(2.175 - 2.1)	(2.082 - 2.01)	(2.279 - 2.2)
Space group	P 31 1 2	P 65 2 2	P 65 2 2
Unit cell	131.73 131.73 151.87	134.2 134.2 231.13	51 51 151.83
Unit cell	90 90 120	90 90 120	90 90 120
Molecules/ASU	4	2	1
Total reflections	557901 (55398)	1264933 (124942)	109448 (10683)
Unique reflections	86483 (8664)	81845 (7989)	6492 (608)
Multiplicity	6.5 (6.4)	15.5 (15.6)	16.9 (17.6)
Completeness (%)	98.46 (99.38)	99.65 (99.37)	99.94 (100.00)
Mean I/sigma(I)	7.86 (2.03)	10.90 (1.30)	15.08 (9.98)
Wilson B-factor	35.61	31.84	27.70
R-merge	0.09175 (0.5615)	0.1781 (3.103)	0.07451 (0.1759)
R-meas	0.09971 (0.6107)	0.1841 (3.206)	0.07692 (0.1812)
R-pim	0.03852 (0.237)	0.04639 (0.8003)	0.01875 (0.04297)
CC1/2	0.995 (0.832)	0.997 (0.373)	0.999 (0.996)
CC*	0.999 (0.953)	0.999 (0.737)	1 (0.999)
Reflections used in			
refinement	86454 (8666)	81781 (7983)	6492 (608)
Reflections used for R-free	1992 (199)	1998 (194)	650 (61)
R-work	0.2080 (0.2749)	0.1885 (0.2915)	0.2336 (0.3189)
R-free	0.2318 (0.3235)	0.2001 (0.2926)	0.2566 (0.3106)
CC(work)	0.949 (0.780)	0.960 (0.611)	0.892 (0.811)
CC(free)	0.932 (0.666)	0.949 (0.687)	0.939 (0.774)
Number of atoms	7136	4079	968
Macromolecules	6393	3248	920
Ligands	12	279	0
Solvent	731	552	48
Protein residues	836	418	116
RMS(bonds)	0.003	0.005	0.004
RMS(angles)	0.77	0.97	0.85
Ramachandran favored (%)	95.53	96.86	96.49
Ramachandran allowed (%)	4.11	3.14	3.51
Ramachandran outliers (%)	0.36	0.00	0.00
Rotamer outliers (%)	0.75	0.58	0.00
Clashscore	0.33	1.03	0.57
Average B-factor	44.18	38.81	26.18
Macromolecules	44.06	37.40	26.06
Ligands	52.53	45.06	
Solvent	45.08	43.93	28.46

# Table 1: Data collection and refinement statistics for Amy13K\_CBMbc and Amy13K\_CBMd

Parentheses indicate statistics for the highest resolution shell.

	$K_{d}$ (M) ± SD			
Construct	β-cyclodextrin	Maltoheptaose	Glycogen (mM/%)) <sup>b</sup>	
CBMa (n=1) <sup>a</sup>	4.6 x10 <sup>-4</sup> ± 7.4 x10 <sup>-5</sup>	1.0 x10 <sup>-3</sup> ± 8.2 x10 <sup>-5</sup>	1.0 x10 <sup>-4</sup> ± 8.2 x10 <sup>-5</sup> (2.3)	
CBMbc (n=2) <sup>a</sup>	3.7 x10 <sup>-4</sup> ± 6.1 x10 <sup>-5</sup>	5.0 x10 <sup>-4</sup> ± 7.0 x10 <sup>-5</sup>	3.0 x10 <sup>-5</sup> ± 5.2 x10 <sup>-6</sup> (0.05)	
CBMde (n=2) <sup>a</sup>	1.0 x10 <sup>-4</sup> ± 9.3 x10 <sup>-5</sup>	8.2 x10 <sup>-6</sup> ± 2.3 x10 <sup>-6</sup>	2.4 x10 <sup>-5</sup> ± 3.5 x10 <sup>-6</sup> (2.4)	
CBMe (n=1) <sup>a</sup>	8.5 x10 <sup>-4</sup> ± 3.2 x10 <sup>-4</sup>	3.1 x10 <sup>-3</sup> ± 9.7 x10 <sup>-4</sup>	6.0 x10 <sup>-4</sup> ± 3.8 x10 <sup>-4</sup> (0.8)	
CBMb-e (n=4) <sup>a</sup>	7.8 x10 <sup>-5</sup> ± 9.8 x10 <sup>-6</sup>	8.4 x10 <sup>-5</sup>	6.8 x10 <sup>-7</sup> ± 3.4 x10 <sup>-7</sup> (0.06)	
CBMa-e (n=5) <sup>a</sup>	9.6 x10 <sup>-5</sup> ± 2.9 x10 <sup>-5</sup>	3.1 x10 <sup>-5</sup>	$3.4 \times 10^{-7} \pm 5.4 \times 10^{-8} (0.1)$	

## Table 2: Binding of CBMs to oligosaccharides and glycogen measured by ITC

<sup>a</sup> To obtain binding affinity it was necessary to fix the value of n. Values were chosen to reflect the number of CBMs present in the construct <sup>b</sup> The mM/% values in parentheses represent the concentration of binding sites in 1% glycogen for this construct, see Experimental Procedures

# Table 3: Binding of CBMs to insoluble, intact starch granules measured by depletion assay

	$K_{\rm d}$ (mg/mL) ± SD				
Construct	HiMaize 260	Corn Starch	Potato Starch	Fibersym	
CBMa	44.6 ± 7.2	23.3 ± 9.3	NB <sup>a</sup>	NB <sup>a</sup>	
CBMbc	32.5 ± 6.8	102.3 ± 35.8	NB <sup>a</sup>	NB <sup>a</sup>	
CBMde	35.2 ± 26.2	31.0 ± 7.9	NB <sup>a</sup>	NB <sup>a</sup>	
CBMb-e	4.6 ± 1.4	15.9 ± 2.9	NB <sup>a</sup>	81.9 ± 17.5	
СВМа-е	14.2 ± 8.0	20.7 ± 4.4	> 100 <sup>b</sup>	40.4 ± 18.6	

<sup>a</sup> No significant binding detected for the range of concentrations used in this assay <sup>b</sup> Binding detected, but did not exhibit saturation within the concentration range tested

### Table 4: Activity of Amy13K towards soluble, insoluble and resistant starch

$k_{\rm cat}/K_{\rm M}~({\rm s}^{-1}~{\rm mg}^{-1}~{\rm mL})\pm{\rm SD}$				
Construct Amylopectin	Corn Starch	HiMaize 260	Potato Starch	
WT $3.1 \times 10^2 \pm 1.8 \times 10^1$	3.8 x10 <sup>-1</sup> ± 3.7 x10 <sup>-2</sup>	7.0 x10 <sup>-1</sup> ± 2.8 x10 <sup>-1</sup>	$7.7 \text{ x10}^{-2} \pm 3.3 \text{ x10}^{-3}$	
$\Delta CBMa$ 2.3 x10 <sup>2</sup> ± 9.5 x10 <sup>1</sup>	8.2 x10 <sup>-2</sup> ± 1.0 x10 <sup>-2</sup>	1.6 x10 <sup>-1</sup> ± 2.8 x10 <sup>-2</sup>	$3.6 \times 10^{-2} \pm 1.0 \times 10^{-3}$	
$\Delta CBMa-c$ 1.2 x10 <sup>2</sup> ± 1.0 x10 <sup>1</sup>	1.4 x10 <sup>-2</sup> ± 6.7 x10 <sup>-4</sup>	3.6 x10 <sup>-2</sup> ± 1.5 x10 <sup>-3</sup>	1.9 x10 <sup>-2</sup> ± 2.4 x10 <sup>-3</sup>	
$\Delta CBMa-e$ 1.2 x10 <sup>2</sup> ± 4.0 x10 <sup>1</sup>	9.2 x10 <sup>-3</sup> ± 1.5 x10 <sup>-3</sup>	$1.8 \times 10^{-2} \pm 1.3 \times 10^{-3}$	$1.5 \text{ x10}^{-2} \pm 4.2 \text{ x10}^{-4}$	


**Figure 1.** Domain organization of Amy13K. The signal sequence and cell wall anchor are indicated in grey, CBMs are indicated in green and the catalytic domain is indicated in red. The numbers along the length of the protein represent the start points of the domains. CBM containing constructs and enzymatic constructs used within this study are shown below. CBM constructs were designed based upon a bioinformatic analysis of where the start and end points of the CBMs could be reasonably predicted. At the top, the CAZy classification for each CBM, including two new families designated as CBMxy and CBMyz, is noted.

**Figure 2.** Crystal structure of Amy13K CBM41d. A) Cartoon diagram of Amy13K\_CBMd (PDB 6AZ5). The putative binding site residues are shown in green and the tryptophans of the binding site are labeled for orientation purposes. B) An overlay of the carbohydrate binding sites of Amy13K\_CBMd and the CBM41 from *T. maritima* pullulanase PulA (PDB 2J73). CBMd binding residues and labels are shown in green, while PulA CBM41 binding residues, bound carbohydrate and labels are shown in blue.

**Figure 3.** Crystal structures of Amy13K\_CBMbc. A) Cartoon diagram of Amy13K\_CBMbc in complex with maltoheptaose (PDB 6B3P) with the carbohydrate chain shown in green. B) A close-up view of the CBMb oligosaccharide binding site. The sugar chain is shown in dark green and hydrogen bonds are indicated by dashed lines. C) A close-up view of the CBMc oligosaccharide binding site. The sugar chain is shown in dark green and hydrogen bonds are indicated by dashed lines. D) An overlay of Amy13K\_CBMb and the CBM26 from *Bacillus halodurans* α-amylase G6 (PDB 2C3H). CBMb residues and bound carbohydrate are shown in green, while those for the *B. halodurans* CBM26 from *B. halodurans* α-amylase G6 (PDB 2C3H). CBMb residues, carbohydrate and labels are shown in green, while those for CBM26 are shown in green, while those for the shown in green, while those for CBM26 are shown in green, while those for the shown in green, while those for CBM26 are shown in green, while those for the shown in green, while those for CBM26 are shown in green, while those for the shown in green, while those for the shown in green, while those for the CBM26 from *B. halodurans* α-amylase G6 (PDB 2C3H). CBMb residues, carbohydrate and labels are shown in green, while those for CBM26 are shown in blue.

**Figure 4**. Affinity electrophoresis of Amy13K CBMs. Proteins are separated with (right) or without (left) the indicated polysaccharide incorporated into the gel at 0.1% final concentration in native-PAGE. Bovine serum albumin (BSA) was loaded as a non-binding control.


Accep



Domain organization of Amy13K. The signal sequence and cell wall anchor are indicated in grey, CBMs are indicated in green and the catalytic domain is indicated in red. The numbers along the length of the protein represent the start points of the domains. CBM containing constructs and enzymatic constructs used within this study are shown below. CBM constructs were designed based upon a bioinformatic analysis of where the start and end points of the CBMs could be reasonably predicted. At the top, the CAZy classification for each CBM, including two new families designated as CBMxy and CBMyz, is noted.

249x157mm (300 x 300 DPI)

Accep



В




Figure 2. Crystal structure of Amy13K CBM41d. A) Cartoon diagram of Amy13K\_CBMd (PDB 6AZ5). The putative binding site residues are shown in green and the tryptophans of the binding site are labeled for orientation purposes. B) An overlay of the carbohydrate binding sites of Amy13K\_CBMd and the CBM41 from T. maritima pullulanase PulA (PDB 2J73). CBMd binding residues and labels are shown in green, while PulA CBM41 binding residues, bound carbohydrate and labels are shown in blue.

76x157mm (300 x 300 DPI)




Figure 3. Crystal structures of Amy13K\_CBMbc. A) Cartoon diagram of Amy13K\_CBMbc in complex with maltoheptaose (PDB 6B3P) with the carbohydrate chain shown in green. B) A close-up view of the CBMb oligosaccharide binding site. The sugar chain is shown in dark green and hydrogen bonds are indicated by dashed lines. C) A close-up view of the CBMc oligosaccharide binding site. The sugar chain is shown in dark green and hydrogen bonds are indicated by dashed lines. D) An overlay of Amy13K\_CBMb and the CBM26 from Bacillus halodurans a-amylase G6 (PDB 2C3H). CBMb residues and bound carbohydrate are shown in green, while those for the B. halodurans CBM26 are shown in aqua. E) An overlay of the carbohydrate binding sites of Amy13K\_CBMb and the CBM26 from B. halodurans a-amylase G6 (PDB 2C3H). CBMb residues, carbohydrate and labels are shown in green, while those for CBM26 are shown in blue.

192x239mm (300 x 300 DPI)




Figure 4. Affinity electrophoresis of Amy13K CBMs. Proteins are separated with (right) or without (left) the indicated polysaccharide incorporated into the gel at 0.1% final concentration in native-PAGE. Bovine serum albumin (BSA) was loaded as a non-binding control.

300x253mm (300 x 300 DPI)

Acce